Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms. FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

Tuoshi Pharmaceutical (Shanghai) Co., Ltd., established on 2016-03-29, Business scope includes technology development in the field of medical technology and biotechnology,technical consulting,Technical Services,technology transfer,Business Management Consulting,Business Consulting,Engaged in the import and export of goods and technology,Re-export trade,Trade and trade agency between enterprises in the region,sales of medicines,storage(In addition to dangerous goods),Simple commercial processing in the region,Trade Advisory Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative tumor immunotherapy and precision treatment drugs to meet the intensive medical needs of cancer patients in China and around the world.CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug development, clinical research, and commercialization. The company has built a rich product pipeline composed of 15 tumor candidate drugs with the combination of tumor immunotherapy as the core.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Eikonizo Therapeutics, Inc. was founded in October 2017 based on discoveries from Dr. Jacob Hooker’s academic lab (at MGH (Massachusetts General Hospital) and the Martinos Center for Biomedical Imaging) around novel small molecule design and human PET neuroimaging agents. ‘Eikonizo’ (ee-kuh-NEE-zo) is Greek for ‘envision’ or ‘imagine’. Eikonizo is developing life-changing therapies by creating brain penetrant and peripherally-restricted small molecules to improve the treatment of human disease.

Quimatryx develops new drugs against epigenetic targets. Their main goal is the development of new selective inhibitors of HDAC6, a epigenetic target related with several diseases, such as cancer, central nervous system diseases or autoimmune disorders.

AnnJi Pharmaceutical is a clinical-stage drug development company that specializes in developing small molecules that address unmet medical needs in the areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, and SBMA (Spinal and bulbar muscular atrophy). The focus of the company is on creating global collaborations and business partnerships in the late-stage product development and commercialization of pharmaceutical drugs.

Shanghai Zhongze Pharmaceutical Technology Co., Ltd., established on 2017-09-08, Business scope includes general items:Engaged in technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Expo Services;translation service;Health Advisory(except for medical diagnosis);Business Consulting(Does not include investment consulting);Business Management Consulting;marketing planning;Corporate Image Planning;computer software development(Audio-visual products,Except for electronic publications);sales of cosmetics.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.